August 10, 2017
RealWorld Dynamix™: Biologic/JAK Switching in RA US 2017
There are currently nine biologics, one biosimilar, and one oral janus kinase (JAK) inhibitor approved for the treatment of rheumatoid arthritis (RA) in the United States. With the more established TNF-inhibiting biologics on the market for nearly two decades, RA treatment protocol and payer policy tend to dictate their use as first-line biologics. However, rheumatologists estimate that every year, roughly one-quarter of their RA patients treated with biologics or Xeljanz are switched from one biologic/JAK to another brand. Treatment protocols for second-line (and subsequent line) therapies are less stringent, resulting in a dynamic switching segment. This study provides independent analysis of the switching market, as the key driver and predictor of future brand share, delivering intelligence that is critical to informing commercial decisions.
About Spherix Global Insights
Spherix Global Insights is a business intelligence and market research company, specializing in renal, autoimmune, neurologic and rare disease markets. Our aim is to apply our commercial experience and unique relationships within core specialty markets to translate data into insight, enabling our clients to make smarter business decisions.